These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 17636329)

  • 1. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.
    Kosmas C; Kallistratos MS; Kopterides P; Syrios J; Skopelitis H; Mylonakis N; Karabelis A; Tsavaris N
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):75-82. PubMed ID: 17636329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-fluorouracil cardiotoxicity is a rare, dose and schedule-dependent adverse event: a prospective study.
    Tsavaris N; Kosmas C; Vadiaka M; Skopelitis E; Kopteridis P; Pamouki S; Efremidis M; Kasparian H; Moisakis I; Sakelariou D; Koufos C
    J BUON; 2005; 10(2):205-11. PubMed ID: 17343330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.
    Tsavaris N; Kosmas C; Vadiaka M; Efremidis M; Zinelis A; Beldecos D; Sakelariou D; Koufos C; Stamatelos G
    Med Sci Monit; 2002 Jun; 8(6):PI51-7. PubMed ID: 12070449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
    J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cardiotoxicity induced by 5-fluorouracil or capecitabine].
    Jensen SA; Baeksgaard L; Petersen LN; Reiter L; Sørensen JB
    Ugeskr Laeger; 2010 Jan; 172(1):48-51. PubMed ID: 20056096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bolus 5-Fluorouracil as an alternative modality to infusion 5-Fluorouracil in a patient with rectal cancer and capecitabine-induced cardiotoxicity.
    Shaib W; Lee V; Saif MW
    In Vivo; 2009; 23(5):821-6. PubMed ID: 19779118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine cardiotoxicity--case reports and literature review.
    Manojlovic N; Babic D; Stojanovic S; Filipovic I; Radoje D
    Hepatogastroenterology; 2008; 55(85):1249-56. PubMed ID: 18795667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
    Deboever G; Hiltrop N; Cool M; Lambrecht G
    Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
    Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
    Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
    Twelves C; Gollins S; Grieve R; Samuel L
    Ann Oncol; 2006 Feb; 17(2):239-45. PubMed ID: 16344278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bolus 5-fluorouracil as an alternative in patients with cardiotoxicity associated with infusion 5-fluorouracil and capecitabine: a case series.
    Saif MW; Garcon MC; Rodriguez G; Rodriguez T
    In Vivo; 2013; 27(4):531-4. PubMed ID: 23812226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
    Hoff PM; Ansari R; Batist G; Cox J; Kocha W; Kuperminc M; Maroun J; Walde D; Weaver C; Harrison E; Burger HU; Osterwalder B; Wong AO; Wong R
    J Clin Oncol; 2001 Apr; 19(8):2282-92. PubMed ID: 11304782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment.
    Molteni LP; Rampinelli I; Cergnul M; Scaglietti U; Paino AM; Noonan DM; Bucci EO; Gottardi O; Albini A
    Breast J; 2010; 16 Suppl 1():S45-8. PubMed ID: 21050310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoropyrimidine-associated cardiotoxicity: revisited.
    Saif MW; Shah MM; Shah AR
    Expert Opin Drug Saf; 2009 Mar; 8(2):191-202. PubMed ID: 19309247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
    Oshaughnessy JA; Blum J; Moiseyenko V; Jones SE; Miles D; Bell D; Rosso R; Mauriac L; Osterwalder B; Burger HU; Laws S
    Ann Oncol; 2001 Sep; 12(9):1247-54. PubMed ID: 11697835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports.
    Brickell K; Porter D; Thompson P
    Br J Cancer; 2003 Aug; 89(4):615-6. PubMed ID: 12915866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
    Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
    Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.
    de Forni M; Malet-Martino MC; Jaillais P; Shubinski RE; Bachaud JM; Lemaire L; Canal P; Chevreau C; Carrié D; Soulié P
    J Clin Oncol; 1992 Nov; 10(11):1795-801. PubMed ID: 1403060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute cardiotoxicity during capecitabine treatment: a case report.
    Bertolini A; Flumanò M; Fusco O; Muffatti A; Scarinci A; Pontiggia G; Scopelliti M
    Tumori; 2001; 87(3):200-6. PubMed ID: 11504378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine cardiac toxicity presenting as effort angina: a case report.
    Lestuzzi C; Crivellari D; Rigo F; Viel E; Meneguzzo N
    J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):700-3. PubMed ID: 20093950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.